MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
Previous PostParticipation terms in the Combined General Meeting
Next PostMedinCell to take part in Jefferies Global Healthcare Conference - London, 14-16 November
